Increased Mortality Associated with Higher Pre-Dialysis Serum Sodium Variability: Results of the International MONitoring Dialysis Outcome Initiative.


Journal

American journal of nephrology
ISSN: 1421-9670
Titre abrégé: Am J Nephrol
Pays: Switzerland
ID NLM: 8109361

Informations de publication

Date de publication:
2019
Historique:
received: 27 09 2018
accepted: 13 11 2018
pubmed: 14 12 2018
medline: 31 3 2020
entrez: 14 12 2018
Statut: ppublish

Résumé

Low serum sodium (SNa) is associated with an increased mortality in chronic hemodialysis (HD) patients. Dialysis patients are thought to have an individual pre-dialysis SNa set-point, yet there is evidence for variability of pre-dialysis SNa in individual patient. In this study, we explored the association of several SNa variability metrics with all-cause mortality in a large patient population from the international MONitoring Dialysis Outcomes (MONDO) Initiative. All adult incident patients from the MONDO database with more than 5 SNa measurements during the first year on HD were included. All patients were required to survive the first year on HD (defined as the baseline). During the subsequent 2 years of follow-up, all-cause mortality was recorded. The following variability indicators were calculated during baseline: mean SNa and its SD; average real variability (ARV, average the absolute distance of the 2 consecutive SNa measurements), and average directional range (DR, the difference between minimum and maximum values). We used Cox Proportional hazard model with bivariate spline terms to analyze the joint association of SNa and SD, ARV and DR, respectively, with all-cause mortality. While conducting the multivariate Cox regression analyses, patients were stratified into 3 groups of DR (Negative DR: -20≤ DR ≤ -6, Null DR: -6< DR < 6 and Positive DR: 6≤ DR ≤20) with the Null DR as the reference group. We included 20,216 patients in the study. A SNa ≤135 mEq/L was observed to be the strongest predictor of evaluated mortality risk. Higher SNa variability (quantified as SD, ARV, and DR) was also associated with an increased mortality irrespective of SNa levels. When compared with higher SD or ARV, greater DR showed a stronger association with an elevated risk of death. Controlling the Cox Proportional hazard models for additional parameters showed consistent results. Higher SNa variability associated with increased all-cause mortality at all levels of SNa. DR of SNa showed the strongest association with mortality and may constitute a Simple and novel prognostic indicator, easily applicable at the bedside.

Sections du résumé

BACKGROUND
Low serum sodium (SNa) is associated with an increased mortality in chronic hemodialysis (HD) patients. Dialysis patients are thought to have an individual pre-dialysis SNa set-point, yet there is evidence for variability of pre-dialysis SNa in individual patient. In this study, we explored the association of several SNa variability metrics with all-cause mortality in a large patient population from the international MONitoring Dialysis Outcomes (MONDO) Initiative.
METHODS
All adult incident patients from the MONDO database with more than 5 SNa measurements during the first year on HD were included. All patients were required to survive the first year on HD (defined as the baseline). During the subsequent 2 years of follow-up, all-cause mortality was recorded. The following variability indicators were calculated during baseline: mean SNa and its SD; average real variability (ARV, average the absolute distance of the 2 consecutive SNa measurements), and average directional range (DR, the difference between minimum and maximum values). We used Cox Proportional hazard model with bivariate spline terms to analyze the joint association of SNa and SD, ARV and DR, respectively, with all-cause mortality. While conducting the multivariate Cox regression analyses, patients were stratified into 3 groups of DR (Negative DR: -20≤ DR ≤ -6, Null DR: -6< DR < 6 and Positive DR: 6≤ DR ≤20) with the Null DR as the reference group.
RESULTS
We included 20,216 patients in the study. A SNa ≤135 mEq/L was observed to be the strongest predictor of evaluated mortality risk. Higher SNa variability (quantified as SD, ARV, and DR) was also associated with an increased mortality irrespective of SNa levels. When compared with higher SD or ARV, greater DR showed a stronger association with an elevated risk of death. Controlling the Cox Proportional hazard models for additional parameters showed consistent results.
CONCLUSION
Higher SNa variability associated with increased all-cause mortality at all levels of SNa. DR of SNa showed the strongest association with mortality and may constitute a Simple and novel prognostic indicator, easily applicable at the bedside.

Identifiants

pubmed: 30544113
pii: 000495354
doi: 10.1159/000495354
doi:

Substances chimiques

Sodium 9NEZ333N27

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Informations de copyright

© 2018 S. Karger AG, Basel.

Auteurs

Xiaoling Ye (X)

Renal Research Institute, New York, New York, USA, xiaoling.ye@rriny.com.

Jeroen P Kooman (JP)

Nephrology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Frank M van der Sande (FM)

Nephrology Department, Maastricht University Medical Centre, Maastricht, The Netherlands.

Bernard Canaud (B)

Fresenius Medical Care, Bad Homburg, Germany.

Stefano Stuard (S)

Fresenius Medical Care, Bad Homburg, Germany.

Michael Etter (M)

Medical Office, Fresenius Medical Care Asia Pacific, Hong kong, China.

Xiaoqi Xu (X)

Medical Office, Fresenius Medical Care Asia Pacific, Hong kong, China.

Cristina Marelli (C)

Medical Office, Fresenius Medical Care Latin America, Buenos Aires, Argentina.

Adrian Guinsburg (A)

Medical Office, Fresenius Medical Care Latin America, Buenos Aires, Argentina.

Albert Power (A)

Richard Bright for Renal Unit, Bristol, United Kingdom.

Len A Usvyat (LA)

Renal Research Institute, New York, New York, USA.
Medical Office, Fresenius Medical Care North America, Waltham, Massachusetts, USA.

Yuedong Wang (Y)

University of California-Santa Barbara, Santa Barbara, California, USA.

Peter Kotanko (P)

Renal Research Institute, New York, New York, USA.
Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Jochen G Raimann (JG)

Renal Research Institute, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH